Concepedia

Author

José Falantes

Hospital Universitario Virgen del RocíoORCID

Also Known As

J Falantes, J. F. Falantes, J. Falantes, J.F. Falantes, Jose F Falantes, Jose F. Falantes, Jose Falantes, Jose Francisco Falantes, Jose-Francisco Falantes, José Falantes

104

Publications

2.7K

Citations

18

H-Index

39

Concepts

All Affiliations

Hospital Universitario Virgen del RocíoInstituto de Biomedicina de SevillaUniversidad de SevillaVall d'Hebron Hospital UniversitariComplejo Hospitalario de Salamanca
JF

About

José Falantes is an author at Hospital Universitario Virgen del Rocío specializing in medicine, hematology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

471

2

Health Sciences

3

3

70

3

Public Health

3

3

43

4

Biostatistics

1

1

12

5

Diabetes

1

1

10

José Falantes

×

31

Publications

2.6K

Citations

18

H-Index

YearCitations

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Hervé Dombret, John F. Seymour, Aleksandra Butrym,

Blood

2015

1.1K

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti,

New England Journal of Medicine

2020

519

Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial

Manuela Aguilar‐Guisado, Ildefonso Espigado, Almudena Martín‐Peña,

The Lancet Haematology

2017

230

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

Guillermo Garcia‐Manero, Valeria Santini, António Almeida,

Journal of Clinical Oncology

2021

75

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

John F. Seymour, Hartmut Döhner, Aleksandra Butrym,

BMC Cancer

2017

71

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti,

Blood

2018

57

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Regina García‐Delgado, Dunia de Miguel, Alicia Bailén,

Leukemia Research

2014

49

Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for Primary Antifungal Prophylaxis

José Falantes, Cristina Calderón, Francisco J. Márquez‐Malaver,

Clinical Lymphoma Myeloma & Leukemia

2013

44

Design of the Randomized, Phase III, QUAZAR AML Maintenance Trial of CC-486 (Oral Azacitidine) Maintenance Therapy in Acute Myeloid Leukemia

Gail J. Roboz, Pau Montesinos, Dominik Selleslag,

Future Oncology

2016

38

Overexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid Leukemia

José Falantes, Pablo Trujillo, José I. Piruat,

Clinical Lymphoma Myeloma & Leukemia

2014

37

Page 1